Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of surufatinib in previously treated small cell lung cancer
ChiCTR2300071990Phase 2Recruiting
- Sponsor
- Liaoning Province Cancer Hospital
- Start
- Jan 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of surufatinib in small cell lung cancer (SCLC), sponsored by Liaoning Province Cancer Hospital. Primary endpoint: Progression-free survival. Started Jan 2022; status: recruiting.
02
Drugs
surufatinib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2300071990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300071990.